Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Y-mAbs Therapeutics
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Target population must have relapsed, progressive or refractory non-hodgkin lymphoma and be ineligible for or have exhausted standard therapeutic options that may prolong survival
The subject must have fluoro-deoxyglucose (FDG)-avid lymphoma with measurable disease
CD38 positive tumor at most recent biopsy (new or archival) documented at central laboratory
Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2
Each subject must sign an ICF indicating that he or she understands the purpose of, and procedures required for the trial and is willing to participate in the trial.
You may not be if
Primary central nervous system lymphoma or known central nervous system involvement with lymphoma
Systemic chemotherapy, radiotherapy, immunotherapy, or major surgery administered within 3 weeks (for nitrosoureas within 6 weeks) prior to the first dose of CD38-SADA
Radioimmunotherapy within 100 days prior to the first dose of CD38-SADA
Autologous stem cell transplantation within 42 days prior to the first dose of CD38-SADA
Treatment with approved CAR-T within 100 days prior to the first dose of CD38-SADA
\>40% lymphoma bone marrow involvement
Clareo Health | Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
